○ Median follow-up:○ 54.8 months○ OS:○ Remained significantly longer with nivolumab plus ipilimumab compared to  chemotherapy in both PD-L1 ≥1% and <1% subgroups.○ HR:○ 0.76 (PD-L1 ≥ 1%) and 0.64 (PD-L1 < 1%), indicating a significant decrease in  the risk of death.○ 4-year OS rates:○ 29% versus 18% (PD-L1 ≥ 1%) and 24% versus 10% (PD-L1 < 1%) for  nivolumab plus ipilimumab versus chemotherapy, respectively.○ Safety profile:○ Consistent with previous studies.○ Rash was the most common irAE.○ Early occurrence of irAEs managed according to guidelines. Here, CD274 is linked to Skin rash.